Amgen, Inc. (AMGN) Posts Solid Q3 Results; Boosts Buyback to $10B; Raises FY11 EPS Guidance
Amgen, Inc. (NASDAQ: AMGN) reported Q3 EPS of $1.40, $0.10 better than the analyst estimate of $1.30. Revenue for the quarter came in at $3.94 billion versus the consensus estimate of $3.87 billion.
Raised its buyback program to $10 billion.
Amgen, Inc. sees FY2011 EPS of $5.15-$5.30, versus prior guidance of $5.00-$5.20 and the consensus of $5.21. Amgen, Inc. sees FY2011 revenue of $15.4-$15.6 billion, versus prior guidance of $15.1-$15.5 billion and the consensus of $15.43 billion.
Raised its buyback program to $10 billion.
Amgen, Inc. sees FY2011 EPS of $5.15-$5.30, versus prior guidance of $5.00-$5.20 and the consensus of $5.21. Amgen, Inc. sees FY2011 revenue of $15.4-$15.6 billion, versus prior guidance of $15.1-$15.5 billion and the consensus of $15.43 billion.